What we do

The threat of infectious diseases and the possibility for epidemic or pandemic spread means our treatment strategies must also be accessible on a global scale. Similarly, cancer risk is generally higher among developing countries and they should also benefit from Viriom’s cutting edge research and development capacities.

Viriom's strategy is based on four main pillars that allow for cost-effective development without compromising innovation:

Viriom's seasoned team, broad IP coverage and strong partnering capabilities allow it to follow the most efficient regulatory paths to accelerate registrations and launches, while optimizing the costs. This business model allows Viriom to address unmet medical needs of global importance with innovative and affordable therapies often including new drug combinations.

Viriom's flexible global access strategy allows the company to address multiple disease targets exemplified by our programs in viral hepatitis, HIV, COVID-19, and seasonal or pandemic influenza, along with an increasing emphasis on cancer.